PTO/SB/08a (08-03.)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10581175	
	Filing Date		2006-05-31	
	First Named Inventor	CASS	SAYRE, ET AL	
	Art Unit		-	
	Examiner Name	ı	-	
	Attorney Docket Numb	er	70313/UST	

				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines wher int Passages or Rele s Appear	
	1								
If you wis	h to a	dd additional U.S. Pate	ent citatio	ı n information pl	ease click the	Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number		Publication Date	of cited Document		Releva	Columns,Lines wher int Passages or Rele ^o s Appear	
	1								
If you wis	h to a	dd additional U.S. Pub	lished Ap	FOREIGN PAT			button	. Add Remove	H
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patentee Applicant of cited Document	or V	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Т5
	1	03106457	wo	A	2003-12-24	Syngenta Ltd			
			-						-
	2	0286346	EP	A	1988-10-12	E.I. Du Pont De Nemours & Co.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10581175	
Filing Date		2006-05-31	
First Named Inventor	CAS	SAYRE, ET AL	
Art Unit		-	
Examiner Name	-	1	
Attorney Docket Numb	er	70313/UST	1

	9429309	lwo	A	1994-12-22	Manak 9 Oa Ina			
	9429309	VVO		1994-12-22	Merck & Co., Inc.			
	9828297	wo	A	1998-07-02	Schering Corporation			
	9964002	wo	A	1999-12-16	Merck & Co., Inc.			
o ad	d additional Fore			•				
		NON-P	ATENT LIT	ERATURE DO	CUMENTS	Remove		
r Cite No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5	
	KAWASAKI T ET AL: "Enantioselective total synthesis of (-)-pseudophrynaminol through tandem olefination, isomerization & asymmetric claisen rearrangement". TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, 2003, Vol. 44, No. 8, pages 1591-1593, page 1592, Compound 12							
o ad	d additional non-	patent literature	document o	itation informat	ion please click the Add I	outton Add		
			EXAMIN	ER SIGNATUR	RE			
ignat	ture				Date Considered			
							3	
i i i	o ad ite o	9964002 ite Include name of (book, magazine publisher, city ar KAWASAKI T ET isomerization & a PUBLISHERS, 20 add additional nongnature	9964002 WO o add additional Foreign Patent Docur NON-P. ite (book, magazine, journal, serial, son publisher, city and/or country whee KAWASAKI T ET AL: "Enantioselect isomerization & asymmetric claisent PUBLISHERS, 2003, Vol. 44, No. 8, or add additional non-patent literature of gnature R: Initial if reference considered, wheth	9964002 WO A o add additional Foreign Patent Document citatio NON-PATENT LIT ite o (book, magazine, journal, serial, symposium publisher, city and/or country where published KAWASAKI T ET AL: "Enantioselective total symisomerization & asymmetric claisen rearrangeme PUBLISHERS, 2003, Vol. 44, No. 8, pages 1591 o add additional non-patent literature document of EXAMINI gnature 8: Initial if reference considered, whether or not cit.	9964002 WO A 1999-12-16 Do add additional Foreign Patent Document citation information p NON-PATENT LITERATURE DO ite (book, magazine, journal, serial, symposium, catalog, etc), publisher, city and/or country where published. KAWASAKI T ET AL: "Enantioselective total synthesis of (-)-pseu isomerization & asymmetric claisen rearrangement". TETRAHED PUBLISHERS, 2003, Vol. 44, No. 8, pages 1591-1593, page 159 Do add additional non-patent literature document citation informate EXAMINER SIGNATURE gnature St. Initial if reference considered, whether or not citation is in confirmation.	9964002 WO A 1999-12-16 Merck & Co., Inc. Do add additional Foreign Patent Document citation information please click the Add button NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when approp (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-is publisher, city and/or country where published. KAWASAKI T ET AL: "Enantioselective total synthesis of (-)-pseudophrynaminol through tank isomerization & asymmetric claisen rearrangement". TETRAHEDRON LETTERS, ELSEVIER PUBLISHERS, 2003, Vol. 44, No. 8, pages 1591-1593, page 1592, Compound 12 Do add additional non-patent literature document citation information please click the Add Inc. EXAMINER SIGNATURE Granture Date Considered	9964002 WO A 1999-12-16 Merck & Co., Inc. NON-PATENT LITERATURE DOCUMENTS Remove ite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. KAWASAKI T ET AL: "Enantioselective total synthesis of (-)-pseudophrynaminol through tandem olefination, isomerization & asymmetric claisen rearrangement". TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, 2003, Vol. 44, No. 8, pages 1591-1593, page 1592, Compound 12 o add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE	

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10581175	
Filing Date		2006-05-31	
First Named Inventor	CAS	SAYRE, ET AL	
Art Unit		-	
Examiner Name	-	A Company of	
Attorney Docket Numb	er	70313/UST	

		CEI	RTIFICATION	STATEMENT		
Plea	ase see 37 CFR 1	.97 and 1.98 to make the appro	priate selection	on(s):		
	from a foreign p		oreign applica		s first cited in any communication e months prior to the filing of the	
OR	!					
	foreign patent of after making rea any individual d	fice in a counterpart foreign a sonable inquiry, no item of info	pplication, and ormation conta	d, to the knowledge of th ined in the information di	cited in a communication from a ne person signing the certification sclosure statement was known to ling of the information disclosure	
	See attached ce	tification statement.				
	Fee set forth in 3	7 CFR 1.17 (p) has been subm	nitted herewith			
V	None					
	ignature of the ap 1 of the signature.	plicant or representative is requ	SIGNAT uired in accord		18. Please see CFR 1.4(d) for the	
Signature /Ret		/Rebecca A. Gegick/ Date (YYY)		Date (YYYY-MM-DD)	2006-07-20	_

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Registration Number

51724

Name/Print

Rebecca A. GEGICK

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.